Using CD19 Universal CAR T Cells to Treat Severe Systemic Lupus Erythematosus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of CD19 Universal CAR T cells in patients with refractory systemic lupus erythematosus (SLE), particularly focusing on children. The study aims to address the limitations of traditional autologous CAR T-cell therapies by utilizing universal CAR T cells derived from healthy donors, which can be produced more efficiently and at a lower cost. Participants will be closely monitored for their response to the treatment and any potential side effects. The trial is designed to provide insights into the therapeutic potential of CAR T-cell therapy for a severe autoimmune condition that significantly impacts organ function.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age:≥5 years old;
2. Diagnosed with SLE according to the 2019 EULAR/ACR SLE classification criteria；Still in moderate to severe disease activity despite ≥3M of high dose glucocorticoids(prednisone≥1mg/kg/d or other equivalent amount of other steriod ), hydroxychloroquine and at least 2 of the following treatments(cyclophosphamide, MMF, azathioprine, methotrexate, cyclosporin, tacrolimus, sirolimus, leflunomide, telitacicept, Beliumab, and rituximab); or Intolerant to standard treatments;
3. SLEDAI 2K score≥8 points;
4. The functions of important organs are basically normal:

   Cardiac function: Left ventricular ejection fraction (LVEF) ≥55% with no obvious abnormality in electrocardiogram; Renal function: eGFR≥30ML/min/1.73m2； Liver function: Asparagus cochinchinensis transase (AST) and Alanine Aminotransferase (ALT)≤3.0 ULN, Total Bilirubin (TBIL) in serum ≤2.0×ULN; Lung function: No serious lung lesions, SpO2≥92%;
5. Met the standards of leukapheresis or intravenous blood collection, No contraindication for cell collection;
6. Negative pregnancy test for female Subjects of childbearing age, agree to take effective contraceptive measures the first year after CAR-T infusion;
7. Participants or their guardians agrees to participate in the clinical trial and sign the informed consent form which indicating that he/she understands the purpose and procedure of the clinical trial and is willing to participate in the study.

Exclusion Criteria:

1. Received CAR T cell therapy previously;
2. Central nervous system (CNS) disease: CNS neurolupus requires intervention within 60 days);
3. Active tuberculosis at the time of screening;
4. Have a history of congenital heart disease or acute myocardial infarction within 6 months prior to screening; Or severe arrhythmias (including multisource frequent supraventricular tachycardia, ventricular tachycardia, etc.); Or combined with moderate to massive pericardial effusion, serious myocarditis, etc; Or patients with unstable vital signs who need hypertensive drugs；
5. Suffer from other diseases that require long-term use of glucocorticoid or high-dose of immunosuppressive agents;
6. Uncontrollable infection, or active infection that requires systemic treatment within 1 week prior to screening；
7. History of organ transplantation or hematopoietic stem cell transplantation, or ≥Grade 2 GVHD within 2 weeks prior to screening；
8. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range; Or hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range; Or positive for human immunodeficiency virus (HIV) antibodies; Or syphilis test positive; Or cytomegalovirus (CMV) DNA test positive;
9. Received live vaccine within 4 weeks before screening;
10. Tested positive in Blood pregnancy test；
11. Previous or concurrent malignancy；
12. Patients who participated in other clinical study within 3 months prior to enrollment;
13. Any other conditions that the investigators deem it unsuitable for the study.

Where it's running

• Children's Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Jianhua Mao — The Children's Hospital of Zhejiang University School of Medicine
• Study coordinator: Jianhua Mao, Prof
• Email: maojh88@zju.edu.cn
• Phone: 0571-86670076

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• In vivo CAR-T therapy Arnovie101 for B cell–mediated autoimmune diseases

  This open-label, single-arm study tests Arnovie101, an mRNA-LNP-based in vivo CAR-T therapy, in adults with relapsed or refractory SLE or AIHA to see if it is safe and how the body handles it.

  Recruiting Early Phase 1 Circunited BioPharma (Shenzhen) Co., Ltd. · Beijing, Beijing Municipality · NCT07629596

• CD19 CAR-T (PTOC1) therapy for refractory systemic lupus erythematosus

  This study will try a fast-made CD19 CAR-T cell treatment called PTOC1 in people aged 5 and older whose lupus has not improved with high-dose steroids and multiple immunosuppressive drugs.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Chongqing · NCT07403097

• Ultra-fast autologous CD19 CAR-T therapy for refractory SLE

  This trial will try ultra-fast autologous CD19 CAR-T cells to see if they can control disease in adults with refractory systemic lupus erythematosus.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Nanjing, Jiangsu · NCT07331467

• Ultra-fast BCMA/CD70 CAR-T therapy for refractory lupus

  This trial will test ultra-fast BCMA/CD70 CAR-T cell therapy in adults with systemic lupus erythematosus that has not responded to standard treatments.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Nanjing, Jiangsu · NCT07318259

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.